BILTRICIDE Drug Patent Profile

Which patents cover Biltricide, and when can generic versions of Biltricide launch?

Biltricide is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in BILTRICIDE is praziquantel. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the praziquantel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Biltricide

A generic version of BILTRICIDE was approved as praziquantel by ENDO OPERATIONS on November 27^th, 2017.

Summary for BILTRICIDE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	146
Clinical Trials:	9
Patent Applications:	3,326
Drug Prices:	Drug price information for BILTRICIDE
What excipients (inactive ingredients) are in BILTRICIDE?	BILTRICIDE excipients list
DailyMed Link:	BILTRICIDE at DailyMed

See drug prices for BILTRICIDE

Recent Clinical Trials for BILTRICIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kanazawa University	Phase 2/Phase 3
Kenya Medical Research Institute	Phase 2/Phase 3
Terik Essential Programs Agency for Development, Kenya	Phase 2/Phase 3

See all BILTRICIDE clinical trials

Pharmacology for BILTRICIDE

Drug Class

Anthelmintic

US Patents and Regulatory Information for BILTRICIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	BILTRICIDE	praziquantel	TABLET;ORAL	018714-001	Dec 29, 1982		DISCN	Yes	No

Expired US Patents for BILTRICIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	BILTRICIDE	praziquantel	TABLET;ORAL	018714-001	Dec 29, 1982

International Patents for BILTRICIDE

See the table below for patents covering BILTRICIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Czechoslovakia	241002	METHOD OF 2-ACYL-4-OXO-HAXAHYDRO-4H-PYRAZINO-(2,1-A-)ISOQUINOLINE DERIVATIVES PREPARATION
U.S.S.R.	631070	METHOD OF OBTAINING DERIVATIVES OF 2-ACYL-4-OXOPYRAZINOISOQUINOLINE OR THEIR SALTS OR THEIR OPTICAL ISOMERS
South Africa	7407253
Switzerland	621788
Austria	346344

BILTRICIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biltricide (Praziquantel)

Introduction to Biltricide (Praziquantel)

Biltricide, known generically as praziquantel, is an anthelmintic medication widely used to treat various parasitic worm infections, including schistosomiasis, clonorchiasis, opisthorchiasis, and other trematode and cestode infections[4].

Market Overview

The global praziquantel market is experiencing significant growth, driven by several key factors.

Global Market Size and Growth

The global praziquantel market size was substantial in 2023 and is projected to grow at a notable compound annual growth rate (CAGR) from 2024 to 2031. This growth is attributed to increasing demand for effective treatments against parasitic infections, particularly in regions where these diseases are prevalent[3].

Regional Analysis

The market is segmented into major regions including North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Each region contributes significantly to the overall market size, with Asia-Pacific expected to be a key growth driver due to the high incidence of parasitic infections in this area[3].

Market Segmentation

The praziquantel market is segmented by form (tablets, suspension, injectables), brand variant (branded, generic), application (schistosomiasis, liver fluke infection, etc.), and end-user (hospitals and clinics, pharmacies, etc.). The tablets segment accounted for a noticeable share of the global market in 2023 and is expected to continue growing[3].

Key Players and Competitive Landscape

Major Manufacturers

Key companies in the praziquantel market include Bayer, Zoetis, Chanelle Pharma, Covetrus, Shin Poong Pharm, Norbrook Laboratories, and Merck KGaA. These companies are focusing on strategies such as expanding their product portfolios, geographical expansion, and research & development to strengthen their market positions[3][5].

Brand and Generic Variants

Both branded and generic versions of praziquantel are available, with the branded segment expected to retain its position throughout the forecast period due to its established reputation and quality[3].

Financial Trajectory

Revenue Growth

The global praziquantel market is witnessing significant revenue growth. This is partly due to the increasing adoption of praziquantel as a treatment for various parasitic infections and the expanding reach of key manufacturers into new markets[3][5].

Cost Analysis

The cost of praziquantel is relatively low, making it an accessible treatment option. For instance, the cost to treat a child with praziquantel is approximately US$0.20, which is a crucial factor in its widespread use, especially in WHO's efforts to eliminate schistosomiasis by 2030[4].

Pricing and Profitability

The pricing of praziquantel varies by region and form. For example, a 600 mg tablet of Biltricide can cost around $14.57 USD, while the powder form is significantly cheaper at $1.06 USD per gram. Despite the low cost, the high volume of sales contributes to substantial revenue for manufacturers[4].

Market Drivers

Increasing Demand for Effective Treatments

The rising incidence of parasitic infections, particularly in developing countries, drives the demand for effective and affordable treatments like praziquantel[3].

WHO Initiatives

The World Health Organization's (WHO) efforts to eliminate schistosomiasis by 2030 have significantly boosted the demand for praziquantel, as it is the recommended drug for treating this disease[1][4].

Technological Advancements

Advancements in drug formulation and delivery systems, as well as improvements in analytical techniques, have enhanced the efficacy and stability of praziquantel, further driving its market growth[1].

Market Challenges

Regulatory Requirements

Manufacturers must comply with stringent regulatory requirements, which can sometimes hinder the rapid expansion of the market. However, these regulations also ensure the quality and safety of the drug[5].

Competition from Generic Versions

The presence of generic versions of praziquantel can pose a challenge to branded products, as generics often offer a cheaper alternative. However, branded products maintain their market share due to their reputation and quality[3].

Future Prospects

Geographical Expansion

Key players are focusing on expanding their geographical reach, particularly into regions with high incidences of parasitic infections. This strategy is expected to drive further growth in the market[5].

Research and Development

Continuous research and development in the field of anthelmintic drugs, including the exploration of new formulations and delivery systems, will likely enhance the market prospects for praziquantel[1].

Strategic Alliances

Manufacturers are adopting strategies such as mergers and acquisitions, and collaborative research to further expand their market presence and develop new products[5].

Conclusion

The praziquantel market, driven by the demand for effective treatments against parasitic infections, is poised for significant growth. Key players like Bayer and Zoetis are leveraging strategies such as geographical expansion, research & development, and strategic alliances to maintain their market positions. The low cost and high efficacy of praziquantel, coupled with WHO initiatives, ensure its continued relevance in the global healthcare landscape.

Key Takeaways

• Global Growth: The praziquantel market is expected to grow significantly from 2024 to 2031.
• Regional Focus: Asia-Pacific is a key growth driver due to the high incidence of parasitic infections.
• Market Segmentation: The market is segmented by form, brand variant, application, and end-user.
• Key Players: Bayer, Zoetis, and Chanelle Pharma are major players focusing on expansion and R&D.
• WHO Initiatives: WHO's efforts to eliminate schistosomiasis by 2030 boost demand for praziquantel.
• Technological Advancements: Improvements in drug formulation and analytical techniques enhance the drug's efficacy.

FAQs

What is the primary use of Biltricide (praziquantel)?

Biltricide (praziquantel) is primarily used to treat parasitic worm infections such as schistosomiasis, clonorchiasis, opisthorchiasis, and other trematode and cestode infections[4].

Which regions are key drivers of the praziquantel market?

The Asia-Pacific region is a significant driver of the praziquantel market due to the high incidence of parasitic infections in this area[3].

What are the major forms of praziquantel available in the market?

Praziquantel is available in various forms including tablets, suspension, and injectables[3].

Who are the major manufacturers of praziquantel?

Key manufacturers include Bayer, Zoetis, Chanelle Pharma, Covetrus, Shin Poong Pharm, and Merck KGaA[3][5].

What is the cost of treating a child with praziquantel?

The cost to treat a child with praziquantel is approximately US$0.20, making it an affordable treatment option[4].

Sources

1. Praziquantel Fifty Years on: A Comprehensive Overview of Its Solid State - PMC.
2. Biotricity reports continued margin improvement and reduced losses in its first quarter fiscal year 2025 - Biotricity.
3. Global Praziquantel Market Report 2024 Edition - Cognitivemarketresearch.
4. Praziquantel: Uses, Interactions, Mechanism of Action - DrugBank.
5. Comprehensive Praziquantel Market Analysis and Future Prospects - Global Banking and Finance.